Moreover, the downregulation of miR-32 found in RCC is considered as a marker of poor prognosis and has been proposed to be indirectly linked to the upregulation of NRF2 observed in RCCs, since in prostate cancer it downregulates PI3K, a known negative regulator of NRF2 [98]. Here, NFE2L2 is linked to prostate cancer.